Kornimate/medical-research-clean huggingface dataset:
valproic acid use in patients with neurological disorders

Conditions: Neurological Disorders

Summary: sodium valproate is a well-known anticonvulsant used in the treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions requiring the administration of mood stabilizers. aim of the present study is to assess sodium valproate usage among patients with neurological disorders. prescriptions of 600 patients from out-patient pharmacy of neurology department at mansoura university teaching hospital were analyzed in a retrospective prospective observational study which conducted between january 2015 and december 2017. data collected include: demographic data, medical history, drug-drug interaction, polypharmacy, medication error, doses and therapeutic duplication. a designed and structured form was used to collect the required information.

this quasi-experimental pretest-posttest design study was conducted at the outpatient's pharmacy of neurology department at tertiary care hospital. after identifying problems with use and completing a follow-up, 3 months of educational intervention (lectures) among professionals was given. as this study is observational informed consent from all subjects was waived. the subjects were enrolled on the basis of inclusion and exclusion criteria. patients receiving at least 7 days of valproic acid, between 10-70 years old, both sexes, were included in the study figure 1. 600 prescriptions were reviewed between january of 2015 to december of 2017 for patients who were suffering from any psychotic illness and were on psychiatric medications. then pharmacist educational intervention started and followed up for three months then prescriptions re-evaluted. inclusion/ exclusion criteria: the study population was limited to those who were continuously eligible for the outpatient pharmacy refilling thier medications during the entire study period. patients were identified through pharmacy drug prescriptions by hospital policy all drugs are prescribed for a maximum period of 3 months. consequently, all patients presented at least twice during the study period. a designed and structured form was used to collect the required information. data then collected on microsoft excel sheet, which included patients' initial therapeutic indications, concomitant use of oral medications, significant adverse drug effects and any drug -drug interaction.

Eligibility criteria:
inclusion criteria: * the study population was limited to those who prescribed with valproate and were continuously eligible for the outpatient during the entire study period. patients were identified through pharmacy drug prescriptions by hospital policy all drugs are prescribed for a maximum period of 3 months. consequently, all patients presented at least twice during the study period. exclusion criteria: * patients who not use valproate.

Keywords: valproate use
acute effects of moderate intensity aerobic exercise on cognitive functions in young adult males

Conditions: Cognitive Change

Summary: 60 healthy male university students will be included in this study. physical fitness parameters, fluid intelligence, and physical activity level will be measured at baseline. participants will be randomised to one of two testing schedules, groups will complete either a 30-minutes aerobic exercise session or a resting control condition. cognitive measures (simple reaction time task, go/nogo task, spatial cueing, n-back task) will be tested before and after the intervention.


Eligibility criteria:
inclusion criteria: * no known psychiatric, cognitive or physical health problems * no limiting issue for performing exercise according to physical activity readiness questionnaire (par-q+) * physical activity level according to international physical activity questionnaire (ipaq) \< 3000 met exclusion criteria: * discomfort/illness that will interfere with physical activity * using any medication or stimulants * having limitations for performing exercise according to physical activity readiness questionnaire (par-q+)

Keywords: acute aerobic exercise cognition university students physical fitness
" comparative evaluation of aggressive gap arthroplasty with minimal gap arthroplasty in the management of tmj ankylosis "

Conditions: Arthoplasty

Summary: the most commonly used protocol in the management of tmj ankylosis is kabans protocol in which 1.5 to 2 cm aggressive resection of bone is recommended which may lead to gap between cranial base and condyle of mandible.1 however, there are certain disadvantages associated with aggressive gap arthroplasty such as pseudo articulation with shortening of the mandibular ramus, premature occlusion on the affected side with a contralateral open bite in unilateral cases,2 in bilateral cases gagging of the posterior teeth and anterior open bite.3 few studies in the literature available agreed that minimum gap arthroplasty i.e. 5 to 8 mm of gap is sufficient for tmj movements in all planes and recurrence of ankylosis is likely to be prevented by interposed material (graft)4 .so, a randomized control study to compare outcomes of minimal gap arthroplasty with aggressive gap arthroplasty for management of tmj ankylosis is planned.

a standardize protocol for each patient will be followed that comprises of case selection, clinincal evaluation, radiographic assessment,treatment planning and measurement of varius parameters. * medical and dental history of the patient will be obtained. * a written consent form signed by the patient, will be obtained. * case evaluation will be done which will include clinical and radiographic evaluation based on the case evaluation, surgical treatment of ankylosis will be performed . patient will be randomized into the following two groups. group a -minimal gap arthroplasty for management of tmj ankylosis group b -aggressive gap arthroplasty for management of tmj ankylosis a minimum of 6 subjects per group completing the study would be giving a good external validity to the present study. 1. all the patients were evaluated with history, clinical and radiological examinations (panoramic and ct scans). informed consent will be obtaine from all the patients. 2. in both groups, all the patients will be operated by an experienced surgeon.the data acquisition will be done by a resident who will be kept blind for group allocation. 3. in group 1 cases treatment of tmj ankylosis will be done by minimal gap arthroplasty and in group 2 cases treatment of tmj ankylosis will be done by aggressive gap arthroplasty 4. both groups cases will be evaluated preoperatively ,intraoperatively and postoperatively follow-up visits will be at 1, 3, and 6 months 5. preoperative and postoperative evaluation will be done clinically ( mouth opening ,protrusive movement, laterotrusive movement ) , radiologically (opg, ctscan) .

Eligibility criteria:
inclusion criteria: * medically healthy adult(asa classification i-ii) * any age group * sawhneys classification type iv * unilateral ankylosis * written informed consent exclusion criteria: * any syndromic patient * recurrence cases * sawhneys classification type i,ii,iii

Keywords: gap arthoplasty
does the relaxation response inhibit acute stress?

Conditions: Healthy

Summary: the purposes of this study are: 1. to examine molecular and biochemical changes, associated with the relaxation response (rr) that can counteract the effects of stress in healthy adults. 2. to compare genomic, molecular and biochemical parameters between healthy adults with a long term meditative practice and those with no experience in meditation. since stress is a factor in the development of many health conditions, a further understanding of the mechanisms of the rr should be developed. the project is designed to determine how the rr can improve the quality of life that has been adversely affected by stress.

the purposes of this study are: 1. to examine molecular and biochemical changes, associated with the relaxation response (rr) that can counteract the effects of stress in healthy adults. 2. to compare genomic, molecular and biochemical parameters between healthy adults with a long term meditative practice and those with no experience in meditation. since stress is a factor in the development of many health conditions, a further understanding of the mechanisms of the rr should be developed. the project is designed to determine how the rr can improve the quality of life that has been adversely affected by stress.

Eligibility criteria:
inclusion criteria: * healthy individual * age:18-49 years * able to read and understand english * able to attend al study visits * access to a telephone (to schedule visits) exclusion criteria: * current smoking * asthma * current use of any prescription or psychoactive medications or supplements * either: 1. no prior experience with rr eliciting techniques 2. at least 3 years of regular rr elicitation (at least 20 min/day) * bmi \>30 * exhaled nitric oxide levels \>60 ppb * abnormal lab values (hct \ 1.3, glucose \>200 * pregnancy

Keywords: nitric oxide, volumetric oxygen consumption
use of amplified sound signal to identify presence of carotid and femoral stenosis

Conditions: Carotid Stenosis; Femoral Arterial Stenosis; Carotid Bruit Asymptomatic; Carotid Murmur

Summary: the purpose of the study is to test a new amplified stethoscope(audiodoc) that can detect the presence of bruit by using an acoustic signal to represent the bruit. this pilot study will address two questions: is there a detectable difference in recorded sound signal of carotid and femoral bruit when compared to sound signals captured when there is no bruit present; is the use of a visual recorded signal more accurate in identifying carotid and femoral bruit when compared to traditional auscultation with a regular stethoscope and ultrasound.

recorded signals are stored on a laptop computer. the signals later undergo fourier analysis are then compared to the findings on carotid ultrasoud as to degree of stenosis. subjects with high grade stenosis in which no bruit was ascultated but in which carotid ultrasound data suggests a bruit may be present are studied for soft /inaudible bruits. when available, data will be correlated to ct/conventional angiographic studies.

Eligibility criteria:
inclusion criteria: * age 19-90 years * having clinical ultrasound evaluation of carotid or femoral artery exclusion criteria: * under age 19; over age 90 years

Keywords: carotid stenosis femoral artery ischemia carotid bruit asymptomatic carotid murmur
hpv genotype attribution and disease burden of anal cancer in china

Conditions: Anal Cancer

Summary: to demonstrate hpv prevalence and its genotype distributions in anal cancer in china and to describe demographic and clinical features of hpv-related anal cancer in china; to describe the epidemiological characteristics ,trends and of disease burden of anal cancer in china


Eligibility criteria:
inclusion criteria: * (1) patients diagnosed with anal cancers, (2) patients without radiation or chemotherapy prior to specimen collection; exclusion criteria: * (1) patients with hiv infection, (2) patients with immunosuppression after solid organ transplantation, (3) those who do not agree to specimen collection and testing, (4) for retrospective study cases, those who without specimen.

Keywords: hpv prevalence hpv genotype anal cancer
apatinib in neoadjuvant therapy for patients with breast cancer

Conditions: Breast Cancer

Summary: to verify the role of apatinib in neoadjuvant therapy for breast cancer, the investigators designed a prospective, randomized, parallel-controlled phase ii/iii trial, to investigate the efficacy and safety of apatinib combined with tp (paclitaxel + cisplatin) or tp regimen alone as neoadjuvant therapy for stage ii-iii breast cancer treatment. 100 cases of eligible patients were diagnosed by core needle biopsy and immunohistochemistry, with the molecular subtypes of triple-negative, her2+ or luminal b, evaluated by pathological complete remission (pcr), objective response rate (orr), adverse events, disease free survival (dfs) and os, aiming at providing a new way for neoadjuvant therapy in breast cancer and anti-angiogenic treatment of malignant tumors.


Eligibility criteria:
inclusion criteria: 1. breast invasive carcinoma diagnosed by core needle biopsy, without previous treatments for breast cancer; 2. with the molecular subtypes of triple-negative, her2+ or luminal b, confirmed by immunohistochemistry; 3. breast cancer within stage iib-iiic, planned to receive neoadjuvant therapy; 4. women aged from 18 to 70 years old; 5. required to have an eastern cooperative oncology group (ecog) performance status of 0 to 1; 6. left ventricular ejection fraction (lvef) greater than 55% without clinical symptoms or signs of heart failure; 7. adequate bone marrow, with white blood cell ≥4.0×109 /l，neutrophils ≥2.0×109 /l, platelet ≥100×109 /l, hemoglobin ≥ 90 g/l； 8. serum creatinine ranges from 44 to 133 mol/l; 9. glutamic pyruvic transaminase and glutamic-oxalacetic transaminase ≤2 times to superior limit of normal value; 10. bilirubin ≤ superior limit of normal value; 11. expected survival ≥ 12 months; 12. pregnancy tests must be negative, and the couples of patients should agree to use effective contraception during treatment and the following one year; 13. approved by the institutional ethnics committee of the fourth hospital of hebei medical university, with signature to the informed consent. exclusion criteria: 1. severe systemic infection; 2. being allergic or intolerant to apatinib, paclitaxel, cisplatin; 3. having received any testing drugs, radiotherapy or other chemotherapy drugs within 30 days before being enrolled in this trial; 4. uncontrolled hypertension, severe heart function; 5. researchers believe that participating in the test does not meet the best interests of the patients (e.g. cause adverse health) or may interfere with the evaluation of response.

Keywords: apatinib neoadjuvant therapy breast cancer
evaluation of endometriosis with 18f-fluorofuranylnorprogesterone pet / mri

Conditions: Endometriosis

Summary: purpose: the aim of this study is to assess the sensitivity and specificity of ffnp pet/mri for diagnosis of endometriosis. participants: a total of 24 participants will be recruited from individuals with clinically suspected endometriosis. procedures (methods): this is a prospective, one arm, single center study of 24 subjects with clinically suspected endometriosis to demonstrate ffnp pet-mri's clinical utility for diagnosis of endometriosis.


Eligibility criteria:
inclusion criteria * age 18 or older * female of childbearing age (18-55 years) * clinically suspected (symptomatic) endometriosis as defined by referring physician (this would also include endometriomas as other disease may be present). * scheduled for planned operative laparoscopy with no hormone treatment for at least two cycles * able to provide informed consent exclusion criteria * male * institutionalized subject (prisoner or nursing home patient) * known history of breast, ovarian or endometrial cancer. * pregnant or breast-feeding women * chronic progestin-containing medications or gonadotropin-releasing hormone (gnrh) analogues in the last 10-16 days (or 2 cycles in the case of gnrh analogues as these are dosed monthly) or inability to discontinue these medications * allergy to gadolinium contrast or glomerular filtration rate (gfr) below 30 ml/min.
safety and tolerability of kh658 gene therapy in subjects with neovascular age-related macular degeneration (namd)

Conditions: Age-related Macular Degeneration

Summary: kh658 is a adeno-associated virus (aav) vector-based gene therapy for suprachoroidal space injection. the long-term, stable therapeutic protein after one time injection for namd could potentially reduce the treatment burden and maintain vision.


Eligibility criteria:
inclusion criteria: 1. are willing and able to sign the informed consent form (icf); 2. female and male aged 50 to 85 years (inclusive) with namd; 3. have previously received anti-vegf treatment for namd, with documented response to anti-vegf therapy and a minimum of 2 anti-vegf ivt injections in the study eye in the 6 months prior to screening; 4. have a etdrs bcva letter score of 83 to 19 (approximately 20/25 to 20/400 snellen equivalent) in the study eye at screening; 5. have a etdrs bcva letter score of ≥19 in the fellow eye at screening; 6. females must be at least 1 year postmenopausal. exclusion criteria: 1. have any other cause of cnv (such as pathological myopia, etc.) in the study eye; or non-namd disease in the study eye judged by the investigator that could impact macular examination or affect central vision (such as diabetic retinopathy, central retinal vein occlusion, etc.); 2. any condition preventing visual acuity improvement in the study eye, e.g. fovea scar, fibrosis or atrophy; 3. have a subretinal hemorrhage that is either 50% or more of the total lesion area, or blood is greater than 1.0 mm2 under the fovea in the study eye at screening; 4. have any vitreous hemorrhage or history of vitreous hemorrhage in the study eye; 5. presence of an implant (excluding intraocular lens), opacification of the refractive medium or miosis that affects fundus examination; 6. have a history of or presence of retinal detachment or choroidal detachment in the study eye.
estradiol plus olaparib for breast cancer (phoebe)

Conditions: Metastatic Breast Cancer

Summary: determine the safety and recommended phase ii dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced er+/her2- breast cancer.

patients with endocrine-resistant er+/her2- breast cancer are eligible. patients will be treated with the combination of 17b-estradiol and olaparib for 2 cycles, and then treated with single-agent 17b-estradiol until disease progression. clinical benefit, progression-free survival, objective response, tumor metabolic response, and toxicity will be determined.

Eligibility criteria:
inclusion criteria: * post-menopausal women with er+/her2- breast cancer. * metastatic or locoregional recurrence not amenable to treatment with curative intent. * received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting. exclusion criteria: * during study treatment, no concurrent anti-cancer therapies are allowed with the following exceptions: o anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) permitted. * any investigational cancer therapy or systemic chemotherapy in the last 3 weeks. * any radiation therapy in the last 2 weeks. * known cns disease, unless clinically stable for ≥ 3 months. * concomitant use of known strong or moderate cyp3a inhibitors. * persistent toxicities (≥ctcae grade 2) caused by previous cancer therapy. * history of any of the following: * deep venous thrombosis * pulmonary embolism * stroke * acute myocardial infarction * congestive heart failure * previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30% * severe renal impairment (creatinine clearance ≤ 30 ml/min).

Keywords: metastatic locally advanced estradiol therapy olaparib
(a novel pharmacologic regime for elective percutaneous coronary intervention)

Conditions: Coronary Artery Disease

Summary: the hypothesis: low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.

aim: primary objective:to evaluate the efficiency and safety of low dose intracoronary unfractioned heparin (ufh) on elective percutaneous coronary intervention (pci). secondary objective: * to evaluate the effect of low dose intracoronary ufh on myocardial ischemia after pci. * to evaluate the effect of low dose intracoronary ufh on bleeding complications after pci. * to evaluate the cost-effectivity of low dose intracoronary ufh on elective pci study central: * bursa postgraduate hospital, cardiology clinic study population: * we planned to enrol 200 patients. * patients will randomise in two groups (control group:100 patients, study group:100 patients) study works:-write case report form for all patients * control for inclusion criteria * demographic data (age, gender) * height, weight, bmi and glomerular filtration rate (gfr) * risk factors * laboratory data (biochemical and hematologic) * medication history * echocardiographic data * angiographic data * procedure time * pci data(vessel diameter, stent diameter, lesion and stent length, performed percutaneous transluminal coronary angioplasty (ptca) or not, etc) * before and after procedure (activated clotting time) act value * before and after procedure troponin i (tni) and creatine kinase mb (ckmb) levels * note complication (mace, bleeding, hematoma etc) * note femoral compression time. 4 weeks later note the first control data. six months later note the second control data.

Eligibility criteria:
inclusion criteria: * the patients; who have planned elective pci and have had written informed consent for participation to study. * the native coronary artery; * lesion with narrowing \>=70%, * lesion without thrombus * no left main coronary artery (lmca) lesion * no chronic total occlusion lesion exclusion criteria: * patients have allergy for acetylsalicylic acid (asa), clopidogrel and heparin * patients who performed primary pci * patients with acute coronary syndrome * patients with have a history of myocardial infarction (mi) for two weeks * patients who were use ufh or low molecular weight heparin (lmwh) for 24 hours * patients on warfarin therapy * patients who have bleeding diathesis, or have high risk for bleeding.

Keywords: percutaneous coronary intervention low dose intracoronary heparin
improving posture in parkinson's patients through home-based training and biofeedback

Conditions: Parkinson's Disease and Parkinsonism; Postural Kyphosis

Summary: a stooped posture is one of the characteristic motor symptoms of patients with parkinson's disease, and has been linked to impairments in adl and qol. we aimed to test the efficacy, safety, practical utility and user-friendliness of a posture correction and vibrotactile trunk angle feedback device (the upright) in the home setting of patients with parkinson's disease with a stooped posture.

the subjects will be asked to arrive at the gait laboratory for mobility research at tel aviv medical center. after a detailed explanation of the research procedure and after signing the consent form, they will be introduced to the upright go device. participances will practice operating and placing the device on the body. with the device attached to upper back, a number of short clinical tests will be performed: 1. complete demographic questionnaires and medical history 2. walking tests and balance: 1. short walks at a comfortable speed with or without dual task. 2. stairs 3. performing daily tasks, such as entering and exiting a room, negotiating obstacles (shoebox), walking between obstacles, buttons, tying laces, carrying small objects on a tray, bringing a glass of water etc. 4. timed "get up and go test" all tests are supervised by a physiotherapist . upon completion of the tests, the upright device will be delivered for use and exercise for 2 months. physiotherapist will guide to maintain the devices (such as charging devices and connecting to power). at the end of the training period, the participans will be invited again to gait lab for post tests.

Eligibility criteria:
inclusion criteria: 1. diagnosis of parkinson's disease, as defined in the uk brain bank criteria 2. hoehn and yahr stage i-iii 3. participants who are at stable medication regimen 4. able to walk independently for at least 5 minutes with or without support of accessory device. exclusion criteria: 1. mini mental state exam (mmse) score\< 24